Form 4: Director Sells LGND Shares Under 10b5-1 Plan

Ligand Pharmaceuticals Director John W. Kozarich sold 467 shares of common stock on March 2, 2026, under a pre-arranged 10b5-1 trading plan.

Summary

• John W. Kozarich, a Director of Ligand Pharmaceuticals Inc. (LGND), sold a total of 467 shares of common stock.
• The sales occurred on March 2, 2026, across multiple transactions.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kozarich on March 7, 2025.
• The shares were sold at weighted-average prices ranging from $197.1397 to $203.57 per share.
• Following these transactions, Mr. Kozarich directly beneficially owns 42,720 shares of Ligand Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event because the sales were conducted under a pre-established 10b5-1 plan, which typically indicates personal financial planning rather than a change in the director's outlook on the company's future.

Positives

• NA

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• NA

Industry Context

StockSavvy.ai notes that routine insider sales under Rule 10b5-1 plans are common across industries, particularly for long-serving executives and directors managing their personal portfolios. These pre-scheduled sales typically do not reflect new information about the company's immediate prospects but rather personal financial planning.

Comparison to Industry Standards

• NA

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: A minor reduction in director ownership, but generally minimal impact due to the pre-planned nature of the sale.

Next Steps

• NA

Key Dates

Recommendation

The insider sale by a director, while reducing their direct ownership, was conducted under a pre-arranged 10b5-1 plan. This suggests personal financial management rather than a bearish view on the company's prospects. The relatively small number of shares sold compared to the director's remaining holdings and the company's overall market capitalization means this transaction alone is unlikely to significantly alter the investment thesis for Ligand Pharmaceuticals. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting more substantive company-specific news or financial results.

Keywords

Ligand Pharmaceuticals, LGND, Insider Trading, Form 4, Stock Sale, Director Transaction, 10b5-1 Plan, John W. Kozarich